Related Experiment Video

Updated: Oct 26, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.0K

Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A

Matteo Santoni1, Francesco Massari2, Enrique Grande3

  • 1Oncology Unit, Macerata Hospital, Macerata, Italy. mattymo@alice.it.

Targeted Oncology
|August 2, 2021
PubMed
Abstract

Insights

Cabozantinib shows activity in patients with metastatic sarcomatoid renal cell carcinoma. Further research is needed to identify biomarkers for selecting patients for targeted therapies.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Renal cell carcinoma (RCC) with sarcomatoid differentiation is an aggressive cancer.
  • Metastatic RCC (mRCC) with sarcomatoid features presents unique treatment challenges.

Purpose of the Study:

  • To evaluate the efficacy of cabozantinib in patients with metastatic sarcomatoid RCC.
  • To identify prognostic factors influencing outcomes in this patient population.

Main Methods:

  • Retrospective analysis of data from 16 international centers.
  • Inclusion of 66 patients with metastatic sarcomatoid RCC treated with cabozantinib.
  • Survival outcomes (overall survival and progression-free survival) analyzed using Kaplan-Meier curves and Cox proportional models.

Main Results:

  • Median progression-free survival was 7.59 months; median overall survival was 9.11 months.
  • Progression-free survival was longer in male patients and those without bone metastases.
  • Female sex, bone metastases, and IMDC criteria were significant predictors of worse overall survival.

Conclusions:

  • Cabozantinib demonstrates activity in pretreated patients with sarcomatoid RCC.
  • Development of biomarkers is crucial for optimizing treatment selection for multi-kinase inhibitors in this aggressive cancer subtype.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K